Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, December 20, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Scientists Identify New and Beneficial Function of Endogenous Retroviruses
Researchers found that ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Long Noncoding RNAs: A Novel Prognostic Marker in Older Patients with Acute Leukemia
This study describes a new marker that might help doctors choose the least toxic, most effective treatment for older patients with acute myeloid leukemia.
Proteins Drive Cancer Cells To Change States
When RNA-binding proteins are turned on, cancer cells get locked in a proliferative state.
Signaling Mechanism Could Be Target For Survival, Growth Of Tumor Cells In Brain Cancer
Non-canonical EGFR signalling shown to make glioblastoma tumor cells more resistant to chemotherapy treatment.
New Way To Turn Genes On
Technique allows rapid, large-scale studies of gene function.
CSHL Team Finds a Way to Make shRNA Gene Knockdown More Effective
A powerful algorithm that improves the effectiveness of an important research technology.
Genes that Cause Pancreatic Cancer Identified by New Tool
Screening system in mice spots cancerous changes invisible to sequencing.
A Yardstick to Measure the Malignancy of Prostate Cancer
Researchers have been searching for regulatory proteins that change the epigenetic characteristics of prostate cancer cells.
Genetic Errors Linked To Aging Underlie Leukemia That Develops After Cancer Treatment
New research by Daniel Link, MD, and colleagues at The Genome Institute at Washington University has revealed that mutations that accumulate randomly as a person ages can play a role in a fatal form of leukemia that develops after treatment for another cancer.
New Cause of Child Brain Tumour Condition Identified
Doctors and scientists have identified changes in SUFU gene which can cause Gorlin syndrome.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn